Novo Nordisk (NYSE: NVO) is the world's largest maker of diabetes and GLP-1 weight-loss drugs. Its Ozempic, Wegovy and Rybelsus franchise (all built on semaglutide) ignited the global obesity treatment revolution and briefly made Novo one of Europe's most valuable listed companies.
Founded in 1923, Novo Nordisk holds roughly one-third of the global diabetes-care market and is the runaway leader in GLP-1 therapies. The mature insulin business funds R&D while GLP-1 drives growth.
GLP-1 (Ozempic and Wegovy) is the primary growth engine across diabetes and obesity; insulin is the cash-generative base; rare disease covers haemophilia and growth hormone; and the pipeline includes oral obesity drugs, CagriSema and Amycretin.
Eli Lilly's Zepbound / Mounjaro (tirzepatide) is taking share aggressively. Drug-pricing pressure in the US and Europe is a persistent headwind. GLP-1 demand has structurally exceeded supply, so manufacturing capacity is a bottleneck, and next-generation trial readouts move the stock directly.
An oral high-dose semaglutide could dramatically expand the addressable weight-loss population. New labels in cardiovascular disease, chronic kidney disease, MASH and sleep apnea unlock large new patient pools. Rising obesity rates across Asia make emerging markets the next major GLP-1 battleground.
Novo Nordisk is the clearest recent case study of how a single blockbuster franchise can rewrite a century-old company. For long-term investors who believe GLP-1 will be one of the largest drug categories of the next decade, competition-driven pullbacks are worth studying carefully.
Note: NVO pays a dividend; total return above assumes dividends are reinvested (DRIP). Past performance is not a guarantee of future results. Data updates daily.